title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
Stocks That Hit 52-Week Lows On Wednesday,20220511T162815,https://www.benzinga.com/markets/options/22/05/27141482/52-weeks-high-and-low-article,ADAP,0.006905,Neutral,0.009332
Stocks That Hit 52-Week Lows On Friday,20220506T160650,https://www.benzinga.com/markets/options/22/05/27050916/52-weeks-high-and-low-article,ADAP,0.005467,Neutral,-0.015143
Stocks That Hit 52-Week Lows On Thursday,20220428T193101,https://www.benzinga.com/markets/options/22/04/26872967/52-weeks-high-and-low-article,ADAP,0.00644,Somewhat-Bearish,-0.301571
"ADCT Awaits Cami Trial Data, CSTL Boosts Revenue Outlook, ANNX To Report HD Trial Data In Q2",20220510T094515,https://markets.businessinsider.com/news/stocks/adct-awaits-cami-trial-data-cstl-boosts-revenue-outlook-annx-to-report-hd-trial-data-in-q2-1031440845,ADAP,0.065452,Neutral,0.000385
Stocks That Hit 52-Week Lows On Tuesday,20220315T163235,https://www.benzinga.com/news/22/03/26148458/stocks-that-hit-52-week-lows-on-tuesday,ADAP,0.00539,Neutral,0.002373
Stocks That Hit 52-Week Lows On Thursday,20220310T165722,https://www.benzinga.com/news/22/03/26083670/stocks-that-hit-52-week-lows-on-thursday,ADAP,0.014015,Neutral,-0.13581
"Gene Therapy Market Set for 19% CAGR Surge, Reaching USD 38.34 Billion by 2031 | SkyQuest Technology",20240912T133000,https://www.benzinga.com/pressreleases/24/09/g40833623/gene-therapy-market-set-for-19-cagr-surge-reaching-usd-38-34-billion-by-2031-skyquest-technology,ADAP,0.039878,Neutral,0.026899
uniQure  ( QURE )  Falls on Mixed Huntington's Disease Study Results,20230622T141700,https://www.zacks.com/stock/news/2111826/uniqure-qure-falls-on-mixed-huntingtons-disease-study-results,ADAP,0.285526,Neutral,0.072191
Adaptimmune  ( ADAP )  Down on End of Collaboration With Roche,20240415T181200,https://www.zacks.com/stock/news/2255611/adaptimmune-adap-down-on-end-of-collaboration-with-roche,ADAP,0.431554,Neutral,0.061446
"Gene therapy market size to grow by USD 4.61 billion from 2022 to 2027, North America is estimated to contribute 39 ... - PR Newswire",20240318T093600,https://www.prnewswire.com/news-releases/gene-therapy-market-size-to-grow-by-usd-4-61-billion-from-2022-to-2027--north-america-is-estimated-to-contribute-39-to-the-growth-technavio-302090363.html,ADAP,0.033562,Neutral,0.019119
"Gene therapy market size to grow by USD 4,613.9 million from 2022 to 2027 | Growing research in gene therapy for ... - PR Newswire",20231201T073500,https://www.prnewswire.com/news-releases/gene-therapy-market-size-to-grow-by-usd-4-613-9-million-from-2022-to-2027--growing-research-in-gene-therapy-for-cvds-and-orphan-diseases-is-the-major-market-trend--technavio-302002646.html,ADAP,0.048523,Neutral,0.017903
"Gene Therapy Market size to grow by USD 4.61 billion from 2022 to 2027, North America to account for 39% of market ... - PR Newswire",20231103T223500,https://www.prnewswire.com/news-releases/gene-therapy-market-size-to-grow-by-usd-4-61-billion-from-2022-to-2027--north-america-to-account-for-39-of-market-growth--technavio-301976707.html,ADAP,0.074692,Neutral,0.0
"Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate",20220804T130628,https://www.benzinga.com/general/biotech/22/08/28353376/biotech-daily-amgen-gilead-go-shopping-nod-for-astrazenecas-lynparza-in-early-stage-breast-cancer,ADAP,0.09989,Neutral,0.0
"Earnings Scheduled For May 9, 2022",20220509T085247,https://www.benzinga.com/news/earnings/22/05/27068359/earnings-scheduled-for-may-9-2022,ADAP,0.019128,Neutral,-0.040046
"Smith & Wesson Brands Reports Upbeat Earnings, Joins America's Car-Mart, HCI Group And Other Big Stocks Moving Higher On Friday - Smith & Wesson Brands  ( NASDAQ:SWBI ) ",20240308T150832,https://www.benzinga.com/news/24/03/37560602/smith-wesson-brands-reports-upbeat-earnings-joins-americas-car-mart-hci-group-and-other-big-stocks-m,ADAP,0.261117,Bullish,0.45695
Buy 5 Top-Ranked Stocks With Rising P/E in July,20230706T113700,https://www.zacks.com/stock/news/2117390/buy-5-top-ranked-stocks-with-rising-pe-in-july,ADAP,0.22616,Somewhat-Bullish,0.169972
12 Health Care Stocks Moving In Tuesday's Pre-Market Session,20220315T130946,https://www.benzinga.com/pre-market-outlook/22/03/26143615/12-health-care-stocks-moving-in-tuesdays-pre-market-session,ADAP,0.128615,Neutral,0.005677
Adaptimmune  ( ADAP )  Surges More Than 80% in a Month: Here's Why,20240116T161700,https://www.zacks.com/stock/news/2210881/adaptimmune-adap-surges-more-than-80-in-a-month-heres-why,ADAP,0.236396,Neutral,0.030949
Adaptimmune  ( ADAP )  Rises as GSK Transfers T-Cell Therapy IND,20231130T155200,https://www.zacks.com/stock/news/2191582/adaptimmune-adap-rises-as-gsk-transfers-t-cell-therapy-ind,ADAP,0.308891,Neutral,0.108306
"Lava  ( LVTX )  Discontinues Hematological Tumor Study, Shares Fall",20230615T134300,https://www.zacks.com/stock/news/2108856/lava-lvtx-discontinues-hematological-tumor-study-shares-fall,ADAP,0.34729,Neutral,0.128581
LAVA Therapeutics Announces Two Appointments to its Board of Directors,20220615T110000,https://www.globenewswire.com/news-release/2022/06/15/2462948/0/en/LAVA-Therapeutics-Announces-Two-Appointments-to-its-Board-of-Directors.html,ADAP,0.038059,Neutral,0.015462
LAVA Therapeutics Announces Two Appointments to its Board of Directors,20220615T110000,https://www.benzinga.com/pressreleases/22/06/g27715260/lava-therapeutics-announces-two-appointments-to-its-board-of-directors,ADAP,0.036694,Neutral,0.015462
"Earnings Scheduled For March 14, 2022",20220314T091110,https://www.benzinga.com/news/earnings/22/03/26116901/earnings-scheduled-for-march-14-2022,ADAP,0.038925,Neutral,0.00023
